We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.008 | 0.52% | 1.556 | 3,646,685 | 16:35:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 1.532 | 1.576 | 1.55 | 1.53 | 1.53 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | -3.98M | -0.0035 | -4.43 | 17.7M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 17:08:10 | O | 60,000 | 1.556 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 25/4/2024 | 12:19 | ALNC |  EARNINGS: LSL starts 2024 "strongly"; Focusrite maintains payout |
| 25/4/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Final Results |
| 28/3/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Total Voting Rights |
| 29/2/2024 | 14:04 | ALNC | Hemogenyx Pharmaceuticals raises money for leukaemia treatment |
| 29/2/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC Placing to Raise US$4.2 million |
| 16/2/2024 | 11:27 | ALNC | Hemogenyx shares rise on potential for CBR to treat brain diseases |
| 16/2/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC CBR Brain Delivery |
| 14/2/2024 | 10:14 | ALNC | Hemogenyx says CBR can be used intranasally to treat viral infections |
| 14/2/2024 | 07:00 | UK RNS | Hemogenyx Pharmaceuticals PLC CBR Intranasal Delivery |
| 09/2/2024 | 10:00 | ALNC | IN BRIEF: Hemogenyx shares surge as FDA lifts Hemo-Car-T trial hold |
Hemogenyx Pharmaceuticals (HEMO) Share Charts1 Year Hemogenyx Pharmaceuticals Chart |
|
1 Month Hemogenyx Pharmaceuticals Chart |
Intraday Hemogenyx Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 30/4/2024 | 11:39 | HEMO | 8,867 |
| 26/4/2024 | 15:05 | Hemogenyx- Official Thread | 1,054 |
| 14/3/2022 | 16:13 | HEMO 2020/21 Discussion MODERATED | 3,217 |
| 11/1/2022 | 12:16 | Hemogenyx - 2021 Entry to clinical status | 288 |
| 09/6/2021 | 15:22 | Hemogemyx - nomoderated | 25 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:08:10 | 1.56 | 60,000 | 933.60 | O |
| 15:25:18 | 1.55 | 31,852 | 494.02 | O |
| 15:20:32 | 1.53 | 163,955 | 2,511.79 | O |
| 15:15:19 | 1.53 | 3,774 | 57.82 | O |
| 14:25:44 | 1.56 | 64,267 | 999.99 | O |
| Top Posts |
|---|
Posted at 30/4/2024 09:20 by Hemogenyx Pharmaceuticals Daily Update Hemogenyx Pharmaceuticals Plc is listed in the Finance Services sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx Pharmaceuticals was 1.55p.Hemogenyx Pharmaceuticals currently has 1,141,999,321 shares in issue. The market capitalisation of Hemogenyx Pharmaceuticals is £17,700,989. Hemogenyx Pharmaceuticals has a price to earnings ratio (PE ratio) of -4.43. This morning HEMO shares opened at 1.53p |
Posted at 26/4/2024 13:34 by purple11 tillywhizz lseulver - good post , Prevail ain’t no naive muppets , they are a professional organisation who backed Hemos science & tossed a wedge in a lot higher than current stock price , I’m sure Vlad & Prevail are investigating all potential avenues for the benefit of Hemo & stockholders including Prevail . Noted by Prevail in Sept RNS Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." Let’s see what next few months bring |
Posted at 02/4/2024 12:54 by dreamtwister reading the pharma rags this morning it brings sadness to see,Redx's plans mirror those of C4X Discovery, which is also exiting AIM dissatisfied with its lack of access to growth capital. I knowledge that Hemogenyx are listed on the Main Market & the option to downgrade to the Aim market which would give Hemogenyx Flexibility to raise further Equity or eclipse Redx/C4x with taking the science private before a Hostile t/o with the present sultry share price or Visa-versa spin off one of the other scientific platforms ! in the event of Privatization Shareholder will receive a dividend should some financial Muscle shows interest ? |
Posted at 02/3/2024 10:15 by apotheki Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful." |
Posted at 29/2/2024 14:15 by apotheki Absolutely spot on Paul, time and time again this happens to the unwary investor and it's scandalous how easy it is to get away with it. Some of the financial press are complicit in this - on a regular basis. Perhaps they are plain lazy and don't do any research before they write a glowing article for a company promote - or perhaps they are just interested in any old story and just haven't got a conscience. Perhaps they don't have any financial experience at all and are just as unwary as some PIs. My tactic now is that if there is a sudden concerted effort by a co. to ramp its share price and its balance sheet is low on cash then if I'm holding the share I sell into the price spike - more often than not there's a fund raise coming soon.Fundraises Generally A pattern seems to be emerging, where speculative companies run out of cash, then they pump the share price with upbeat-sounding RNSs. Shortly afterwards they announce a discounted placing into any subsequent share price rise. Private investors speculating on these shares, buying the price rises, seem to be lambs to the slaughter. It doesn't seem right to me that shares are still trading, when the company is secretly offering discounted shares to larger investors in placings. It's often obvious from the share price that news has leaked. We really do need the rules changed (and/or enforced), so that shares are suspended when any company decides to do a fundraise. Also we need quicker, cheaper mechanisms for companies to raise cash. In the meantime, there's a simple way to avoid being clobbered by a discounted placing - don't buy or hold any share where the company doesn't have a cash runway of well over 12 months. Ideally investments should be companies which are profitable and cash generative, hence won't ever need to raise more cash just to keep the lights on. Jam tomorrow/ blue sky shares are a graveyard for optimistic investors, avoiding these things has been the biggest boost for my personal portfolio returns. That said, the odd one multibags, which is what excites people. |
Posted at 29/2/2024 07:40 by apotheki Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented:"We are extremely pleased to have raised these funds to allow us to progress our lead asset, HEMO-CAR-T, to clinical trials. This is a key development that represents the progression of Hemogenyx Pharmaceuticals to become a clinical stage company and the fundraise was crucial to enable us to progress toward clinical trials, the essential next step for the development of HEMO-CAR-T. I would like to thank new and existing shareholders for their support and for contributing to this sizeable fundraise in difficult market conditions. The recent lifting of the clinical hold by the FDA on our HEMO-CAR-T programme followed a great effort from everyone at Hemogenyx Pharmaceuticals for which I am very grateful." |
Posted at 21/2/2024 14:55 by apotheki Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC· Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals. · Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023. Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000). The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital. The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners. Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study. The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study." Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." |
Posted at 17/2/2024 14:10 by apotheki Sounds as though 2024 is going to be one hell of a year....Hemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options. Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections. As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike. Proactive interview:::: |
Posted at 16/2/2024 16:55 by apotheki HemoGenyx Pharmaceuticals / LSE:HEMOHemogenyx Pharmaceuticals achieves breakthrough with HEMO-CAR-T program, CBR platform HemoGenyx Pharmaceuticals (LSE:HEMO) CEO Dr Vladislav Sandler and non-executive director Peter Redmond joined Proactive's Stephen Gunnion after the company pioneering breakthrough treatments for life-threatening diseases, including blood and solid cancers, achieved a number of significant milestones. Sandler highlighted the company's significant progress with its HEMO-CAR-T program after it received the green light from the US Food and Drug Administration (FDA) to enter Phase 1 clinical trials for acute myeloid leukaemia, marking its transition to a clinical-stage biopharmaceutical company. This development symbolizes a pivotal milestone, offering potential life-changing treatments for patients with limited options. Additionally, Hemogenyx is advancing its proprietary Chimeric Bait Receptor (CBR) platform, announcing that it has demonstrated in vivo that the CBR can be delivered intranasally in the form of messenger RNA (mRNA) for the potential treatment of airborne viral infections. As 2024 unfolds, Hemogenyx anticipates starting clinical trials and advancing its CBR platform towards IND-enabling studies, signaling a landmark year with promising outcomes for investors and patients alike. Proactive interview:::: |
Posted at 16/2/2024 08:55 by apotheki 18 September 2023Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Hemogenyx Pharmaceuticals Announces Strategic Investment from Prevail Partners, LLC · Prevail Partners, LLC to invest in Hemogenyx Pharmaceuticals. · Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023. Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that Prevail Partners, LLC ("Prevail Partners"), an investment fund, has agreed to invest in the Company through a subscription for 11,066,667 ordinary shares (the "New Ordinary Shares") at a price of US$0.075 per share (approximately £0.06) for the total sum of $830,000 (approximately £668,000). The subscription price represents a premium of approximately 240% to the Company's closing share price on 14 September 2023, when agreement was reached as to the final terms of the investment. The agreement governing the subscription (the "Subscription Agreement") contains customary warranties from the Company and Prevail Partners. Following allotment, Prevail Partners will hold approximately 0.96% of the Company's issued share capital. The Company's wholly owned subsidiary, Hemogenyx Pharmaceuticals LLC, has also signed a Master Service and Technology Agreement ("MSTA") with Prevail InfoWorks, Inc. ("InfoWorks"), a Philadelphia, PA based Contract Research Organization (CRO) and affiliate of Prevail Partners. Under the terms of the MSTA, InfoWorks is to provide clinical services and technologies for the Company's upcoming Phase I study of its anti-FLT3 chimeric antigen receptor-redirected T cells ("CAR-T cells") in subjects with relapsed/refractory acute myeloid leukemia (AML). Services include clinical site coordination, project management, data management, clinical monitoring, and pharmacovigilance (safety management) services, and the use of InfoWorks' integrated real-time data analytics platform, The Single Interface®, for clinical support and real-time data analysis. The MSTA has an initial term of 40 months, and Hemogenyx Pharmaceuticals LLC has agreed an initial statement of works relating to the Phase I AML study. The subscription funds will in large part defray the payment made by the Company for the first stage of the work being undertaken by InfoWorks under the MSTA. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "As we seek to bring the curative power of cell therapies to a greater number of patients suffering from otherwise incurable life-threatening diseases, we are very confident in Prevail InfoWorks' ability to coordinate our Phase I clinical trial in relapsed/refractory AML. Their operational experience and expertise will enable a smooth execution of the study, while their specialization in real-time data integration and analytics will ensure fast, reliable data access to lower our clinical risk and potentially speed up our regulatory timeline. Prevail Partners' strategic investment in the Company demonstrates their confidence in our CAR-T program and in our ability to execute the upcoming clinical study." Mary Schaheen, President of Prevail Partners, stated: "Everyone at our fund is confident in the growth and success of Hemogenyx Pharmaceuticals as they develop CAR-T cells to target acute myeloid leukemia. Furthermore, Hemogenyx Pharmaceuticals has a seasoned management team with the expertise to accelerate the company to a significant value inflection point through the completion of its planned clinical trial." |
Posted at 15/2/2024 14:25 by apotheki Is it just my screen but the HEMO share price/trades etc page does not look as though it is working properly today? |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
